Zhejiang CONBA Pharmaceutical Co Ltd (600572) - Net Assets

Latest as of September 2025: CN¥7.16 Billion CNY ≈ $1.05 Billion USD

Based on the latest financial reports, Zhejiang CONBA Pharmaceutical Co Ltd (600572) has net assets worth CN¥7.16 Billion CNY (≈ $1.05 Billion USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥10.13 Billion ≈ $1.48 Billion USD) and total liabilities (CN¥2.97 Billion ≈ $434.89 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Zhejiang CONBA Pharmaceutical Co Ltd asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥7.16 Billion
% of Total Assets	70.67%
Annual Growth Rate	17.13%
5-Year Change	29.22%
10-Year Change	51.42%
Growth Volatility	30.69

Zhejiang CONBA Pharmaceutical Co Ltd - Net Assets Trend (2001–2024)

This chart illustrates how Zhejiang CONBA Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Zhejiang CONBA Pharmaceutical Co Ltd for the complete picture of this company's asset base.

Annual Net Assets for Zhejiang CONBA Pharmaceutical Co Ltd (2001–2024)

The table below shows the annual net assets of Zhejiang CONBA Pharmaceutical Co Ltd from 2001 to 2024. For live valuation and market cap data, see market cap of Zhejiang CONBA Pharmaceutical Co Ltd.

Year	Net Assets	Change
2024-12-31	CN¥6.91 Billion ≈ $1.01 Billion	-5.95%
2023-12-31	CN¥7.35 Billion ≈ $1.08 Billion	+0.35%
2022-12-31	CN¥7.32 Billion ≈ $1.07 Billion	-0.92%
2021-12-31	CN¥7.39 Billion ≈ $1.08 Billion	+38.19%
2020-12-31	CN¥5.35 Billion ≈ $782.79 Million	+8.23%
2019-12-31	CN¥4.94 Billion ≈ $723.27 Million	-14.67%
2018-12-31	CN¥5.79 Billion ≈ $847.64 Million	-0.87%
2017-12-31	CN¥5.84 Billion ≈ $855.11 Million	+30.20%
2016-12-31	CN¥4.49 Billion ≈ $656.77 Million	-1.69%
2015-12-31	CN¥4.57 Billion ≈ $668.05 Million	+35.46%
2014-12-31	CN¥3.37 Billion ≈ $493.18 Million	+30.05%
2013-12-31	CN¥2.59 Billion ≈ $379.22 Million	+6.18%
2012-12-31	CN¥2.44 Billion ≈ $357.14 Million	+51.39%
2011-12-31	CN¥1.61 Billion ≈ $235.90 Million	-6.06%
2010-12-31	CN¥1.72 Billion ≈ $251.12 Million	+49.56%
2009-12-31	CN¥1.15 Billion ≈ $167.90 Million	+24.77%
2008-12-31	CN¥919.66 Million ≈ $134.58 Million	+7.59%
2007-12-31	CN¥854.74 Million ≈ $125.08 Million	+36.18%
2006-12-31	CN¥627.66 Million ≈ $91.85 Million	+5.47%
2005-12-31	CN¥595.08 Million ≈ $87.08 Million	+5.31%
2004-12-31	CN¥565.05 Million ≈ $82.68 Million	+135.99%
2003-12-31	CN¥239.44 Million ≈ $35.04 Million	+19.27%
2002-12-31	CN¥200.75 Million ≈ $29.38 Million	+10.37%
2001-12-31	CN¥181.89 Million ≈ $26.62 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Zhejiang CONBA Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 10359.3% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Retained Earnings	CN¥3.64 Billion	53.31%
Common Stock	CN¥2.58 Billion	37.88%
Other Components	CN¥601.35 Million	8.82%
Total Equity	CN¥6.82 Billion	100.00%

Zhejiang CONBA Pharmaceutical Co Ltd Competitors by Market Cap

The table below lists competitors of Zhejiang CONBA Pharmaceutical Co Ltd ranked by their market capitalization.

Company	Market Cap
Makalot Industrial Co Ltd TW:1477	$1.65 Billion
Yunnan Salt & Salt Chemical Industry Co Ltd SHE:002053	$1.65 Billion
Qingdao Gaoce Technology Co Ltd SHG:688556	$1.65 Billion
PLUXEE NV PA:PLX	$1.65 Billion
Mister Car Wash, Inc. Common Stock NYSE:MCW	$1.65 Billion
Choice International Limited NSE:CHOICEIN	$1.65 Billion
Metrics Master Income Trust AU:MXT	$1.65 Billion
Fagron NV BR:FAGR	$1.65 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Zhejiang CONBA Pharmaceutical Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 7,041,063,708 to 6,819,709,642, a change of -221,354,066 (-3.1%).
Net income of 622,417,035 contributed positively to equity growth.
Dividend payments of 523,535,776 reduced retained earnings.
Share repurchases of 299,987,133 reduced equity.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	CN¥622.42 Million	+9.13%
Dividends Paid	CN¥523.54 Million	-7.68%
Share Repurchases	CN¥299.99 Million	-4.4%
Other Changes	CN¥-20.25 Million	-0.3%
Total Change	CN¥-	-3.14%

Book Value vs Market Value Analysis

This analysis compares Zhejiang CONBA Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.62x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 32.82x to 1.62x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2001-12-31	CN¥0.14	CN¥4.45	x
2002-12-31	CN¥0.15	CN¥4.45	x
2003-12-31	CN¥0.18	CN¥4.45	x
2004-12-31	CN¥0.39	CN¥4.45	x
2005-12-31	CN¥0.41	CN¥4.45	x
2006-12-31	CN¥0.38	CN¥4.45	x
2007-12-31	CN¥0.55	CN¥4.45	x
2008-12-31	CN¥0.54	CN¥4.45	x
2009-12-31	CN¥0.60	CN¥4.45	x
2010-12-31	CN¥0.93	CN¥4.45	x
2011-12-31	CN¥0.79	CN¥4.45	x
2012-12-31	CN¥1.21	CN¥4.45	x
2013-12-31	CN¥1.16	CN¥4.45	x
2014-12-31	CN¥1.35	CN¥4.45	x
2015-12-31	CN¥1.79	CN¥4.45	x
2016-12-31	CN¥1.76	CN¥4.45	x
2017-12-31	CN¥2.26	CN¥4.45	x
2018-12-31	CN¥2.15	CN¥4.45	x
2019-12-31	CN¥1.75	CN¥4.45	x
2020-12-31	CN¥2.00	CN¥4.45	x
2021-12-31	CN¥2.75	CN¥4.45	x
2022-12-31	CN¥2.69	CN¥4.45	x
2023-12-31	CN¥2.74	CN¥4.45	x
2024-12-31	CN¥2.74	CN¥4.45	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Zhejiang CONBA Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 9.13%
The company has moderate efficiency in generating returns from equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 9.55%
• Asset Turnover: 0.66x
• Equity Multiplier: 1.45x
Recent ROE (9.13%) is below the historical average (12.81%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2001	23.74%	10.94%	0.86x	2.51x	CN¥24.50 Million
2002	21.21%	9.49%	0.95x	2.35x	CN¥22.11 Million
2003	16.87%	8.55%	0.81x	2.45x	CN¥16.32 Million
2004	5.53%	4.75%	0.61x	1.89x	CN¥-23.17 Million
2005	8.17%	5.04%	0.75x	2.16x	CN¥-9.79 Million
2006	15.00%	6.60%	1.02x	2.23x	CN¥28.15 Million
2007	12.54%	8.58%	0.80x	1.83x	CN¥21.52 Million
2008	10.09%	8.40%	0.70x	1.72x	CN¥857.81K
2009	10.15%	7.20%	0.73x	1.93x	CN¥1.49 Million
2010	12.67%	10.31%	0.77x	1.60x	CN¥41.07 Million
2011	19.72%	12.40%	0.76x	2.08x	CN¥138.15 Million
2012	13.60%	10.82%	0.60x	2.09x	CN¥78.26 Million
2013	17.63%	14.27%	0.66x	1.88x	CN¥180.61 Million
2014	19.79%	15.42%	0.57x	2.26x	CN¥273.30 Million
2015	10.63%	8.31%	0.55x	2.31x	CN¥26.22 Million
2016	10.25%	7.33%	0.71x	1.97x	CN¥10.61 Million
2017	12.41%	13.43%	0.56x	1.64x	CN¥138.22 Million
2018	14.43%	11.62%	0.66x	1.90x	CN¥250.17 Million
2019	-7.41%	-5.11%	0.69x	2.11x	CN¥-811.87 Million
2020	9.02%	7.67%	0.64x	1.85x	CN¥-49.32 Million
2021	28.57%	30.72%	0.61x	1.53x	CN¥1.31 Billion
2022	5.18%	5.97%	0.55x	1.58x	CN¥-333.27 Million
2023	8.40%	8.79%	0.60x	1.60x	CN¥-112.53 Million
2024	9.13%	9.55%	0.66x	1.45x	CN¥-59.55 Million

Industry Comparison

This section compares Zhejiang CONBA Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $4,691,234,838
Average return on equity (ROE) among peers: 6.16%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Zhejiang CONBA Pharmaceutical Co Ltd (600572)	CN¥7.16 Billion	23.74%	0.42x	$1.65 Billion
Shenzhen Neptunus Bioengineering Co Ltd (000078)	$903.62 Million	4.28%	2.45x	$1.16 Billion
Anhui Fengyuan Pharmaceutical Co Ltd (000153)	$1.22 Billion	5.35%	1.27x	$441.99 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423)	$9.87 Billion	20.71%	0.25x	$5.01 Billion
Livzon Pharmaceutical Group Inc (000513)	$1.07 Billion	3.83%	0.46x	$2.80 Billion
Wedge Industrial Co Ltd (000534)	$1.15 Billion	11.42%	1.59x	$3.04 Billion
Yunnan Baiyao Group Co Ltd (000538)	$9.03 Billion	25.71%	0.43x	$13.75 Billion
Hainan Haiyao Co Ltd (000566)	$275.57 Million	17.28%	1.12x	$947.33 Million
Tus Pharmaceutical Group Co Ltd (000590)	$231.22 Million	-38.13%	1.23x	$389.67 Million
Northeast Pharmaceutical Group Co Ltd (000597)	$4.29 Billion	2.31%	2.07x	$1.03 Billion
Jilin Aodong Pharmaceutical Group Co Ltd (000623)	$18.87 Billion	8.83%	0.08x	$3.32 Billion

About Zhejiang CONBA Pharmaceutical Co Ltd

SHG:600572 China Drug Manufacturers - Specialty & Generic

Market Cap

$1.65 Billion

CN¥11.29 Billion CNY

Market Cap Rank

#7028 Global

#1646 in China

Share Price

CN¥4.45

Change (1 day)

-0.67%

52-Week Range

CN¥4.06 - CN¥4.94

All Time High

CN¥10.42